Trials / Active Not Recruiting
Active Not RecruitingNCT04257162
HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- SOLTI Breast Cancer Research Group · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
HER2-Predict is a multi-center, observational study using biological samples from patients treated with DS-8201a in the metastatic setting. Patients will provide a baseline FFPE tumor sample and additionally, blood sample for ctDNA determination will be collected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Tumor and Blood sample collection | This is a non-interventional protocol and does not provide study drug or specific requirements for how the patients should be treated. Nevertheless, patients participating in T-DXd trials included in this study are those who were randomized to receive T-DXd. Tumor sample and blood sample will be collected within the framework of HER2-Predict Study |
Timeline
- Start date
- 2019-12-13
- Primary completion
- 2025-06-30
- Completion
- 2028-05-01
- First posted
- 2020-02-05
- Last updated
- 2025-09-09
Locations
15 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT04257162. Inclusion in this directory is not an endorsement.